PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.23%
Positive revenue growth while CVE is negative. John Neff might see a notable competitive edge here.
-2.71%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-72.59%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-72.59%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-233.51%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-236.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-236.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.55%
Dividend reduction while CVE stands at 0.54%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-50.59%
Negative OCF growth while CVE is at 16.19%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-186.73%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-3.08%
Negative 10Y revenue/share CAGR while CVE stands at 148.51%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-78.20%
Negative 5Y CAGR while CVE stands at 148.51%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-0.83%
Negative 3Y CAGR while CVE stands at 69.74%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
8.61%
10Y OCF/share CAGR under 50% of CVE's 25.71%. Michael Burry would worry about a persistent underperformance in cash creation.
-77.02%
Negative 5Y OCF/share CAGR while CVE is at 25.71%. Joel Greenblatt would question the firm’s operational model or cost structure.
-49.86%
Negative 3Y OCF/share CAGR while CVE stands at 47.66%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-222.60%
Negative 10Y net income/share CAGR while CVE is at 40.86%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-123.68%
Negative 5Y net income/share CAGR while CVE is 40.86%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-496.00%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-21.02%
Negative equity/share CAGR over 10 years while CVE stands at 2.84%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-77.23%
Negative 5Y equity/share growth while CVE is at 2.84%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-70.38%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
637.70%
10Y dividend/share CAGR above 1.5x CVE's 15.04%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
-86.79%
Negative 5Y dividend/share CAGR while CVE stands at 15.04%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-73.54%
Negative near-term dividend growth while CVE invests at 20.65%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
114.38%
Our AR growth while CVE is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
81.02%
We show growth while CVE is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-4.00%
Negative asset growth while CVE invests at 2.10%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.91%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-0.48%
We’re deleveraging while CVE stands at 3.46%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
21.70%
We expand SG&A while CVE cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.